Navigation Links
Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
Date:3/4/2013

MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee voted 10 to 4 that the overall risk/benefit profile of low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) is not acceptable to support approval. LDMP is an investigational nonhormonal treatment specifically developed for moderate to severe vasomotor symptoms (VMS) associated with menopause.

Additionally, the committee voted:

  • 7 to 7 that, based on pre-specified analyses, there is sufficient evidence to conclude that LDMP is effective in treating moderate to severe VMS associated with menopause; and
  • 10 to 4 that, based on pre-specified analyses, there is not sufficient evidence to conclude that the change from baseline in VMS frequency is clinically meaningful to women.

The FDA is not bound by the recommendations of its advisory committees, but will consider their guidance during the ongoing review of the New Drug Application (NDA) that was submitted for LDMP in August 2012. The scheduled Prescription Drug User Fee Act (PDUFA) action date for LDMP is June 28, 2013.

"As conveyed during Noven's presentation, we believe our clinical trial data support LDMP as a safe, effective nonhormonal treatment option offering clinical benefit to menopausal women," said Joel S. Lippman , M.D., Noven's Executive Vice President – Product Development and Chief Medical Officer. "While we are disappointed in today's outcome, we appreciate the discussion and will work closely with the FDA as it completes its ongoing evaluation."

Moderate to severe VMS affect approximately 24 million menopausal women in the United States and approximately two-thirds are not currently treating their VMS with either prescription medication or over-the-counter supplements. There are currently no FDA-approved nonhormonal options for the treatment of VMS.

About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners, with a focus on treatment options for women experiencing menopausal vasomotor symptoms. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., and serves as Hisamitsu's U.S. growth platform in prescription pharmaceuticals. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.hisamitsu.co.jp/english.

Contacts
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916

Samantha Schwarz
Executive Director
GolinHarris
312-729-4370


'/>"/>
SOURCE Noven Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... COSTA MESA, Calif. (PRWEB) , ... December 04, 2019 , ... ... of Mind and Medicine, an Orange County drug and alcohol rehab center ... Outreach Program! Members of their team conducted street outreach, trained, and distributed Naloxone amongst ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... for improved financial, operational and clinical health for our partners, today announced ... the American College of Healthcare Executives (ACHE). , ACHE is an international ...
(Date:12/4/2019)... ... December 04, 2019 , ... Intelligent.com, a trusted resource for ... in Organizational Psychology Degree Programs for 2020. The comprehensive research guide is based ... program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... December 06, 2019 , ... COMPLIANCY GROUP is ... the Wyoming Medical Society. Compliancy Group is dedicated to educating and assisting Wyoming ... to adhere to the standards set forth by the Health Insurance Portability and ...
(Date:12/6/2019)... ... December 06, 2019 , ... Dr. Scott Howell, a 2019 ... published research on the health benefits of coconut oil in the 7 November 2019 ... Effects on the Cardiometabolic Profile: A Structured Literature Review,” led by Dr. Hector O. ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... Risks and Rewards of Building Platforms— on Thursday, December 12, 2019, at 1:00 ... large, multi-specialty medical groups. Middle-market PE firms are scrambling to assemble regional platforms ...
(Date:12/5/2019)... ... December 05, 2019 , ... Today at M Health Fairview ... newest staff member who will to help them take medicine, relax during anxious ... procedures.  , Rocket, presented by NutriSource® is a golden retriever and the first ...
(Date:12/4/2019)... ... December 04, 2019 , ... WEDI , the nation’s leading ... information exchange and a trusted advisor to the U.S. Department of Health and Human ... was announced during the 2019 WEDI Winter Conference in Arlington, Va. on Wednesday, December ...
Breaking Medicine News(10 mins):